Sign In
Last checked at 
4 Sep 2014 07:00
ο»Ώ
4 September 2014
Β
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Β
Shareholder update
Β
Allergy Therapeutics plc (AIM: "AGY" or the "Company"), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that CFR Pharmaceutical SA ("CFR"), a company associated with the Weinstein family and the largest shareholder in Allergy Therapeutics, will release its interim results for the period ended 30 June 2014 on the 4 September 2014. In order that CFR can comply with its reporting requirements Allergy Therapeutics has made the following unaudited financial information below available to CFR.
Β
Balance Sheet as at 31 March 2014
Β
Β£ '000 | |
Total Non-Current Assets | 14,426 |
Total Current Assets | 18,219 |
Total Current Liabilities | (5,339) |
Total Non-Current Liabilities | (6,436) |
Total Equity | 20,870 |
Β
Consolidated Income Statement for the 6 months ended 31 March 2014
Β
Β£'000 | |
Revenue | 27,426 |
Profit after tax for the period | 5,503 |
Β
Items have the same meaning as disclosed in Allergy Therapeutics plc's accounts for the year ended 30 June 2013.
Β
-Ends-
Β
Β
For further information
Β
Allergy Therapeutics | +44 (0) 1903 845 820 |
Manuel Llobet, Chief Executive Officer | |
Ian Postlethwaite, Finance Director | |
www.allergytherapeutics.com | |
Peel Hunt LLP | +44 (0) 20 7418 8900 |
James Steel / Clare Terlouw | |
FTI Consulting | +44 (0) 20 3727 1000 |
Simon Conway / Victoria Foster Mitchell / Mo Noonan |
Β
Β
Notes to editors
Β
About Allergy Therapeutics
Β
Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business with expected revenue of Β£45.7million, before milestones and rebates and supported by a foreign exchange benefit of Β£2.3million, an increase of 14% on the previous year (2013:Β£39.9milllion) achieved mainly in Europe through its own sales and marketing infrastructure and further afield through distributors.
Follow the stocks
